Answer

Caution is strongly advised. Taking licorice with GI prokinetics (specifically cisapride) may increase the risk of toxicity due to a significant drug-supplement interaction.

Evidence Assessment

Quality Score: 35/100 (Tier D - Preliminary/Weak Evidence) The assessment is based on pharmacological mechanism data (CYP450 enzyme inhibition) rather than clinical trial data. While the biochemical pathway is well-understood, there are no specific randomized controlled trials (RCTs) documenting this exact interaction in humans.

Clinical Evidence

The interaction is driven by the effect of licorice on the cytochrome P450 enzyme system. Licorice acts as a moderate inhibitor of CYP3A4, the primary enzyme responsible for the metabolism of certain GI prokinetics, such as cisapride.

When CYP3A4 is inhibited, the clearance of the medication from the bloodstream is reduced, leading to increased plasma concentrations of the drug. Because cisapride has a narrow therapeutic index and is associated with serious cardiac risks (such as QT interval prolongation and Torsades de Pointes) when levels become too high, this interaction is classified as critical.

Practical Guidance

• Populations Affected: This interaction primarily affects individuals taking prokinetic agents that are CYP3A4 substrates.
• Timing: Because enzyme inhibition can occur rapidly, avoiding licorice throughout the entire duration of prokinetic therapy is recommended.
• Forms: This risk applies to both whole licorice root and concentrated extracts containing glycyrrhizic acid.

Safety & Interactions

Interaction Verdict: CAUTION / HIGH RISK

• Drug Class: GI Prokinetics (specifically CYP3A4 substrates like cisapride).
• Mechanism: Moderate inhibition of CYP3A4, leading to decreased drug metabolism and increased systemic exposure.
• Clinical Management:
  • Monitoring: Patients must be monitored closely for signs of prokinetic toxicity or cardiac arrhythmias.
  • Dosing: A dose reduction of the prokinetic may be necessary if licorice use is unavoidable, though avoidance is preferred.
  • Alternatives: Consider using Deglycyrrhizinated Licorice (DGL), which has had the glycyrrhizic acid removed and is less likely to interfere with these metabolic pathways.
• High-Risk Populations: Use extreme caution in patients with pre-existing cardiac conditions (long QT syndrome) or those with hepatic impairment, as their ability to metabolize drugs is already compromised.